Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 belzutifan study in von Hippel-Lindau disease-associated renal cell carcinoma
2023-509119-99-00Phase 2Authorised
- Sponsor
- Peloton Therapeutics, Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of belzutifan in von Hippel-Lindau disease-associated renal cell carcinoma (VHL-RCC), sponsored by Peloton Therapeutics, Inc. Primary endpoint: Overall response rate. Planned start Jul 2024; status: authorised.
02
Drugs
belzutifan
03
Conditions
von Hippel-Lindau disease-associated renal cell carcinoma (VHL-RCC)
Beyond the preview
Go deeper on 2023-509119-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509119-99-00.